newsfilter
← Latest News
PR Newswire·

AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $20.9 million in